All companies

Brand Owners & Retailers

Aceso Therapeutics

Ecosystem Private
Headquarters
Montpellier, FR
Segment
Brand Owners & Retailers
Stories held
0
Last story
—

Aceso Therapeutics is a France-based biotech developing ACT-101, an inhaled antisense oligonucleotide candidate targeting the CFTR F508del mutation in cystic fibrosis, building on research from the PhyMedExp laboratory. It is a customer for inhalation device and formulation services from packaging and drug-delivery suppliers such as Aptar Pharma.

No story yet. Stories on this site are written by AI from public sources and checked by a second AI system before they appear; nothing is shown before that check.